The Costs and Efficacy of Liposomal Doxorubicin in Platinum-Refractory Ovarian Cancer in Heavily Pretreated Patients
- 30 September 2001
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 82 (3) , 464-469
- https://doi.org/10.1006/gyno.2001.6299
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian CancerGynecologic Oncology, 2001
- Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian CancerJournal of Clinical Oncology, 2000
- Phase 2 Trial of Liposomal Doxorubicin (40 mg/m2) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the PeritoneumGynecologic Oncology, 2000
- Outcomes Research in Oncology: History, Conceptual Framework, and Trends in the LiteratureJNCI Journal of the National Cancer Institute, 2000
- Phase II Trial of Vinorelbine in Recurrent and Progressive Epithelial Ovarian CancerGynecologic Oncology, 1999
- Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or PaclitaxelJournal of Clinical Oncology, 1999
- Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.Journal of Clinical Oncology, 1998
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.Journal of Clinical Oncology, 1996
- Oral etoposide is active against platinum-resistant epithelial ovarian cancer.Journal of Clinical Oncology, 1994